ArticleMicrobial cell factories2026
Engineering Komagataella phaffii for secreted and surface-displayed production of SARS-CoV-2 receptor-binding domain and its immunogenicity evaluation.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe receptor-binding domain (RBD) of the SARS-CoV-2 spike protein represents a key antigen for vaccine development due to its critical role in the ACE2 receptor recognition. Yeast-based expression systems, particularly Komagataella phaffii, offer scalable and cost-effective platforms for recombinant protein production. In addition to secretion, cell surface display provides an alternative strategy enabling direct antigen delivery, including applications via mucosal routes.
resultsIn this study, we engineered K. phaffii strains for the production of SARS-CoV-2 RBD in two formats: as a secreted recombinant protein and as a cell surface-displayed antigen using a Sag1 anchoring system. Incorporation of glycine-serine linkers enhanced secretion efficiency, yielding up to 50 mg/L of RBD, with minimal intracellular retention. Western blot analysis indicated the presence of glycosylated forms of RBD, and the recombinant protein was subsequently purified for further characterization. Surface localization of RBD was validated by immunofluorescence microscopy and quantitative fluorescence measurements. Immunogenicity studies in mice demonstrated that intraperitoneal administration of purified RBD elicited a strong humoral immune response. Importantly, sera from immunized animals efficiently inhibited spike protein binding to the Ace2 receptor, indicating potent neutralizing activity. Comparable results were obtained following oral administration of K. phaffii cells displaying RBD on their surface, demonstrating the feasibility of a whole-cell yeast-based vaccine approach.
conclusionsA yeast-based system enabling both secretion and surface display of SARS-CoV-2 RBD has been developed. Both delivery strategies, intraperitoneal administration of the purified protein and oral administration of recombinant yeast cells, induced robust and functionally relevant immune responses in mice. These findings highlight the potential of K. phaffii as a versatile system for the development of cost-effective subunit and oral vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.